Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s share price dropped 13.5% on Monday . The company traded as low as $1.32 and last traded at $1.35. Approximately 1,689,247 shares changed hands during trading, an increase of 86% from the average daily volume of 906,220 shares. The stock had previously closed at $1.56.
SNSS has been the subject of a number of recent research reports. Zacks Investment Research raised Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research report on Saturday, January 19th. Oppenheimer set a $6.00 price objective on Sunesis Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 8th. HC Wainwright reissued a “hold” rating and issued a $0.50 price objective on shares of Sunesis Pharmaceuticals in a report on Tuesday, March 12th. Finally, ValuEngine raised Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Sunesis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $2.33.
The firm has a market cap of $105.43 million, a P/E ratio of -1.80 and a beta of 2.66.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. On average, sell-side analysts anticipate that Sunesis Pharmaceuticals, Inc. will post -0.66 EPS for the current year.
An institutional investor recently bought a new position in Sunesis Pharmaceuticals stock. Aisling Capital Management LP purchased a new stake in shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,600,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,092,000. Sunesis Pharmaceuticals comprises about 1.2% of Aisling Capital Management LP’s investment portfolio, making the stock its 12th biggest position. Aisling Capital Management LP owned approximately 6.95% of Sunesis Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 22.83% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Sunesis Pharmaceuticals (SNSS) Stock Price Down 13.5%” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.thelincolnianonline.com/2019/04/15/sunesis-pharmaceuticals-snss-stock-price-down-13-5.html.
Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Read More: Investing in Dividend Stocks
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.